Download the Protocol

Tesamorelin

Tesamorelin helps the body release more natural growth hormone, supporting metabolism, body composition, and fat reduction research. It is being studied for its role in reducing abdominal fat and improving energy balance.

Description

• Tesamorelin is a stabilized synthetic analog of growth hormone–releasing hormone (GHRH).
• Approved in some countries for reducing excess abdominal fat in HIV-associated lipodystrophy.
• Studied for GH-axis modulation, lipid metabolism, and visceral fat redistribution.

How It Works

• Stimulates the pituitary to release endogenous growth hormone (GH) by binding to GHRH receptors.
• Increases circulating GH and IGF-1 while maintaining natural hormonal feedback loops.
• Enhances lipid oxidation, reduces visceral adipose tissue, and improves metabolic parameters.

Documented Effects

• Increases GH and IGF-1 levels in human and animal trials.
• Reduces visceral fat and improves triglyceride metabolism in metabolic studies.
• Supports better sleep quality, recovery, and energy balance through restored GH rhythm.

Theoretical Effects

• Potential research uses include studying age-related GH decline, metabolic health, and body composition optimization.
• Not approved for aesthetic or performance use outside clinical supervision.

Pharmacokinetics

• Half-life: approximately 30 minutes after subcutaneous administration.
• GH peak: 1–2 hours post-injection due to pituitary response.
• IGF-1 elevation: may persist for up to 24 hours after dosing.

Duration of Effects

• Metabolic and GH-related effects can last up to 24 hours per injection.
• Steady-state GH-IGF-1 elevation achieved after 2–3 weeks of consistent use.
• Benefits fade gradually after discontinuation.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 10 mg of Tesamorelin
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~28 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• 100–200 mcg subcutaneous (SC) once daily, preferably before sleep.
• Conservative entry: 100 mcg for 5–7 days to assess GH response.

Common Research Range

• 200–500 mcg SC daily depending on experimental purpose.
• Evening or pre-sleep administration aligns with natural GH secretion peaks.

Maximum Research Range

• Up to 2 mg SC daily in human clinical studies.
• Higher doses offer no additional GH increase once receptor saturation is reached.

Standard Cycle Length

• 8–12 weeks typical per study cycle with GH and IGF-1 level monitoring.
• Follow with 2–4 week pause before subsequent cycles.

Clinical Notes

• Administer via subcutaneous injection in the abdomen, away from the navel.
• Rotate injection sites to minimize irritation.
• Nighttime dosing optimizes GH synergy with natural circadian rhythm.
• Stable for about 28 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Possible mild flushing, tingling, headache, or injection-site redness.
• Monitor blood glucose and IGF-1 levels during prolonged studies.
• Research compound only — not for therapeutic human use.